Table 1

Determinants of seropositivity among HPV-16 DNA positive women at enrollment; Demographic and sexual factors.

Women characteristics

Anti-HPV16

Unadjusted

Final model1


Negative

Positive

%

OR

(95% CI)

OR

(95% CI)


All women

179

305

63.0

Age

18-19

50

84

62.7

1.00

1.00

20-21

58

79

57.7

0.81

(0.50-1.32)

0.74

(0.44-1.25)

22-23

37

71

65.7

1.14

(0.67-1.94)

0.98

(0.51-1.86)

24-25

34

71

67.6

1.24

(0.73-2.13)

1.04

(0.53-2.06)

p trend

0.27

0.73

Age at sexual debut

≥ 18

53

83

61.0

1.00

1.00

17

33

63

65.6

1.22

(0.71-2.10)

1.22

(0.71-2.10)

16

37

60

61.9

1.04

(0.61-1.77)

1.04

(0.61-1.77)

15

34

57

62.6

1.07

(0.62-1.85)

1.07

(0.62-1.85)

< 15

22

42

65.6

1.22

(0.66-2.27)

1.22

(0.66-2.27)

p trend

0.69

0.69

Years since first sexual intercourse

≤ 1

23

27

54.0

1.00

1.00

2-3

45

75

62.5

1.42

(0.73-2.77)

1.28

(0.65-2.55)

4-5

45

74

62.2

1.40

(0.72-2.73)

1.23

(0.62-2.46)

≥ 6

66

129

66.2

1.66

(0.89-3.13)

1.40

(0.72-2.73)

p trend

0.15

0.39

Frequency sexual intercourse, month

≤ 1

46

48

51.1

1.00

1.00

2-3

26

52

66.7

1.92

(1.03-3.57)

1.85

(0.98-3.46)

4-9

59

110

65.1

1.79

(1.07-2.99)

1.55

(0.91-2.65)

≥ 10

45

92

67.1

1.96

(1.14-3.36)

1.57

(0.89-2.77)

p trend

0.03

0.20

Lifetime number of sexual partners

1

49

63

56.3

1.00

1.00

2

58

92

61.3

1.23

(0.75-2.03)

1.48

(0.87-2.50)

≥ 3

72

150

67.6

1.62

(1.02-2.59)

1.96

(1.19-3.25)

p trend

0.04

0.01

Time with most recent partner, months

< 4

52

69

57.0

1.00

1.00

4-13

56

98

63.6

1.32

(0.81-2.15)

1.24

(0.75-2.05)

> 13

71

138

66.0

1.46

(0.92-2.32)

1.54

(0.92-2.58)

p trend

0.11

0.10


NOTE. HPV, human papillomavirus; OR, odds ratio; CI, confidence interval.

1 For each variable considered the final model adjusts for all variables that changed the crude estimate of risk by 15% or more.

Age: was adjusted for years since first sexual intercourse.

Age at sexual debut: was not adjusted for any co-factors since none of the potential confounders evaluated changed the OR estimates by 15% or more.

Years since first sexual intercourse: was adjusted for use of hormonal contraceptives.

Frequency sexual intercourse, month: was adjusted for use of hormonal contraceptives.

Lifetime number of sexual partners: was adjusted for time with most recent partner.

Time with most recent partner: was adjusted for lifetime number of sexual partners and use of hormonal contraceptives.

Porras et al. BMC Infectious Diseases 2010 10:238   doi:10.1186/1471-2334-10-238

Open Data